Drug Combination Details
| General Information of the Combination (ID: C45714) | |||||
|---|---|---|---|---|---|
| Name | Neferine NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Doxorubicin induced apoptosis was potentiated by neferine in human lung adenocarcima, A549 cells. Food Chem Toxicol. 2014 Jun;68:87-98. | |||
